{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 10.6 Appendix 6:', 'Modified:', 'To enhance monitoring of liver', 'Liver Safety - Actions and', 'parameters during the conduct of', 'Discussion of possible', 'Follow-up Assessments', 'the trial', 'Investigational Product (IP)', 'continuation or', 'discontinuation if ALT or', 'AST > 3 X ULN or total', 'bilirubin or direct bilirubin', '1.5 X ULN and potential', 'triggering of appropriate', 'follow-up to include Liver', 'Safety Laboratory', 'assessments', 'ALT or AST > 1 X ULN and', '< 3 X ULN or total bilirubin', 'or direct bilirubin > 1 X ULN', 'and VI 1.5 X ULN, confirm the', 'value within 24 to 48 hours', 'Global Change', 'Minor revisions to text', 'Administrative updates were', 'incorporated, and typographical', 'errors were corrected', '84', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Amendment 3 (v3.0; 28 Aug 2019)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall Rationale for the Amendment:', 'The primary purpose of this amendment is to enhance monitoring of liver parameters during the', 'conduct of the trial and to provide guidance on drugs that may be associated with hepatoxicity', 'and provide clarification on eligibility criteria.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.3 Schedule of', 'Notes on total bile acid,', 'Addition of INR', 'Activities;', 'international normalized ratio', 'measurement at baseline.', 'Section 1.2 Schema', '(INR), and fractionation of', 'Collection of a total bile acid', 'ALP if ALP > 1xULN were', 'sample at every visit, and', 'added.', 'fractionation of ALP if ALP', 'Added assessment of clinical', '> 1xULN.', 'chemistry at Week 3.', 'Week 3 visit was added to', 'Added separate line for', 'enhance laboratory', 'concomitant medications.', 'monitoring during the first', 'month following IP initiation.', 'Clarified timing of', 'concomitant medications.', 'Section 2.3.1 GB001', 'Revised data for GB001.', 'Clarified risk/benefit profile.', 'Risk/Benefit Assessment', 'Section 5.1', 'Maximum age was increased.', 'Higher maximum age allowed', 'because no additional risk is', 'Inclusion Criterion #2', 'expected in this extended', 'population.', 'Section 5.2', 'Clarified polypectomy performed', 'Polypectomy performed as an', 'Exclusion Criteria #2', 'as an outpatient procedure will', 'outpatient procedure is', 'not exclude subject from study.', 'considered a minor surgery.', 'Section 5.2', 'Added known history of non-', 'Clarified liver-related pre-existing', 'alcoholic fatty liver disease', 'conditions.', 'Exclusion Criteria #5', \"(NAFLD) or Gilbert's Syndrome.\", 'Section 5.3', 'Updated nasal polyp score (NPS)', 'Clarified that subjects with NPS', 'Randomization Criteria #2', 'range for exclusion from', 'of 0 are eligible for', 'randomization.', 'randomization.', 'Section 5.3', 'Added maximum absolute', 'Enhance safety characterization', 'Randomization Criteria #6', 'eosinophil count and white blood', 'of the study population', 'cell (WBC) count criteria.', 'Section 6.5.1 Prohibited', 'Added the concept of', 'Increased awareness of', 'Medications Prior to the', 'restricted medications.', 'medications which may', 'Screening Visit and', 'Referred investigators to list', 'impact liver effects and those', 'Throughout the Study;', 'of medications in Appendix', 'drugs/agents that may inhibit', '10 which include those', 'or induce CYP3A.', '85', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 10.10 Appendix 10:', 'medications known to have', 'Intranasal corticosteroid', 'Prohibited Medications and', 'the potential for drug induced', 'delivered via a specialized', 'Treatments', 'liver injury (DILI) as well as', 'device will be allowed under', 'CYP3A inhibitors and', 'Inclusion Criteria #6.', 'inducers.', 'Removed XHANCET as', 'a', 'prohibited medication.', 'Section 8 Study Assessments', 'Added language on nasal', 'Clarified which subjects should', 'and Procedures', 'endoscopy and nitric oxide', 'receive nasal endoscopy and that', 'measurement at Randomization', 'all subjects should have nitric', 'visit.', 'oxide measurement.', 'Section 8.1.2 Computed', 'Updated language that prior CT', 'Clarification that a prior CT', 'Tomography (CT)', 'may be acceptable under specific', 'within 60 days of the', 'conditions.', 'Randomization visit of', 'satisfactory quality may be', 'acceptable.', 'Section 10.2 Appendix 2:', 'Total bile acid, INR, and', 'To enhance monitoring of liver', 'Clinical Laboratory Tests', 'fractionation of ALP if ALP >', 'parameters during the conduct of', 'Table 3', '1xULN were added.', 'the trial.', 'Global Change', 'Minor revisions to text.', 'Administrative updates were', 'incorporated, and typographical', 'errors were corrected.', '86', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}